Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - November 10, 2003
The Kampala-based Quality Chemicals (QC), which for the past three months has been importing generic ARVs from Indian-based Cipla Pharmaceuticals, told IRIN recently that it planned to set up a factory to manufacture ARVs before the end of next year.
"We are working closely with the Ministry of Health and Uganda AIDS Commission to have this facility in place," the QC managing director, Emmanuel Katongole, said. "Our proposal is still being negotiated with Cipla. What is important is that everyone -us, the patients, government, the aid agencies and our suppliers in Cipla - wants this to happen. We should be able to find a way."
He said both companies were examining the project's commercial prospects with a view to slashing the price as low as possible, while still retaining some profit.
He added that the project was not just to cut the price of the drugs, but in order to make sure that ARVs were "continuously available, and can be planned for, not subject to sporadic imports".
But AIDS campaigners have urged caution over such claims, warning that the move towards producing ARVs in Uganda could take longer than either the companies or the Government are willing to admit.
"There are a lot of things that have to be done before you can start producing drugs in a factory," said Rosette Mutambi of the Coalition for Health Promotion and Social Development.
"I don't see how they will get this up so fast. I suspect this is partly a publicity exercise for the company.
In the meantime, we need to look at getting our hands on cheaper drugs and more of them," she says.
At the 11th conference of the Global Network for People Living with HIV/AIDS, in Kampala recently, participants unveiled a bid by the Clinton Foundation which, they said, had managed to procure ARVs between US $120 and $140 for a year's treatment.
031110
NV031109
Copyright © 2003 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .